Petzer, Andreas L.
Sperr, Wolfgang R.
Buxhofer-Ausch, Veronika
Sliwa, Thamer
Schmidt, Stefan
Greil, Richard
Wölfler, Albert
Pichler, Petra
Dormann, Clemens
Burgstaller, Sonja
Tinchon, Christoph
Lang, Alois
Goebel, Florian
Uthman, Shanow
Muenchmeier, Niklas
Valent, Peter
Funding for this research was provided by:
Johannes Kepler University Linz
Article History
Received: 5 December 2019
Accepted: 23 May 2020
First Online: 12 June 2020
Conflict of interest
: A.L. Petzer – Advisory board member and honoraria recipient of Novartis, BMS, Pfizer, and Incyte. Travel support from BMS and Pfizer. W.R. Sperr – Fee from Novartis and Pfizer. V. Buxhofer-Ausch and T. Sliwa declare that they have no competing interests. S. Schmidt – Consultant of BMS. Research Grant from Incyte/Ariad. Advisory board participation and CML registry of Pfizer. R. Greil – Honoraria recipient, consulting or advisor, research funding, travel support, accommodation and expenses from Celgene, Roche, Merck, Takeda, Astra Zeneca, Novartis, Amgen, BMS, MSD, Sandoz, Abbvie, and Janssen. A. Wölfler – Honoraria recipient of Novartis, BMS, Pfizer, and Incyte. P. Pichler declare that she has no competing interests. C. Dormann – Advisory board member of Pfizer and Eli Lilly. Travel support from Novartis, Pfizer, Roche, MDS, Angelini, Ipsen, and Celgene. Speaker honoraria recipient of Roche, Bristol-Myers Squibb, MDS, Pierre Fabre, and AstraZeneca. S. Burgstaller – Advisory board member, travel support, and speaker honoraria recipient of Novartis, AOP Orphan, Celgene, and Takeda. C. Tinchon declare that he has no competing interests. A. Lang – Grant from Novartis. F. Goebel, S. Uthman and N. Muenchmeier – Employees of Novartis. P. Valent – Grant from Celgene and Pfizer. Fee from Novartis, Celgene, Pfizer, Incyte, and Deciphera.